Compared side by side
Tirzepatide vs VK2735: how they differ
The short answer
Both are weekly shots that switch on the same two receptors, GLP-1 and GIP: tirzepatide was the first such dual agonist, and VK2735, from Viking Therapeutics, takes the same approach and is also being tested as a daily tablet. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; VK2735 has been in phase 3 since June 2025 and isn’t approved anywhere. In its 13-week phase 2 trial, people on VK2735 lost about 9% to 15% of their body weight depending on the dose, and tirzepatide’s 15 mg produced up to 22.5% at 72 weeks (SURMOUNT-1).
Side by side
| Compared | Tirzepatide | VK2735 |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Mounjaro, Zepbound, LY3298176 | VK-2735, VK 2735 |
| What it is | The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). | A weekly GLP-1 and GIP dual agonist from Viking Therapeutics, the same two-receptor approach as tirzepatide, also being tested as a daily tablet. |
| How it works | Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management. | Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, the same pair tirzepatide works through. A side chain stretches its half-life to about 7 to 10 days in people, long enough for weekly shots. The idea is the one tirzepatide proved: two incretin signals that curb appetite and food intake together. Viking also makes it as a daily tablet, the same molecule by mouth. Investigational, in phase 3 since June 2025. |
| Commonly reported | Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound). | In trials, nausea and other GI effects early on, fading as the dose holds. It is in phase 3 and not approved anywhere. |
| Studied range | FDA label: 2.5–15 mg, starting dose 2.5 mg. | Research range: 2.5–17.5 mg, starting dose 2.5 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~5 days (FDA label) | ~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose. | Used continuously, once weekly, in its trials: 13 weeks in phase 2 and 78 weeks in phase 3. In Viking's maintenance study, people who switched after 21 weekly doses to a shot every other week or once a month kept most of their loss over the next 12 weeks; on placebo they kept about 61%. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue | Nausea, constipation, diarrhea, vomiting, acid reflux, fatigue, dry mouth |
- Category
- TirzepatideMetabolic & GLP-1
- VK2735Metabolic & GLP-1
- Also known as
- TirzepatideMounjaro, Zepbound, LY3298176
- VK2735VK-2735, VK 2735
- What it is
- TirzepatideThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
- VK2735A weekly GLP-1 and GIP dual agonist from Viking Therapeutics, the same two-receptor approach as tirzepatide, also being tested as a daily tablet.
- How it works
- TirzepatideDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.
- VK2735Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, the same pair tirzepatide works through. A side chain stretches its half-life to about 7 to 10 days in people, long enough for weekly shots. The idea is the one tirzepatide proved: two incretin signals that curb appetite and food intake together. Viking also makes it as a daily tablet, the same molecule by mouth. Investigational, in phase 3 since June 2025.
- Commonly reported
- TirzepatideVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).
- VK2735In trials, nausea and other GI effects early on, fading as the dose holds. It is in phase 3 and not approved anywhere.
- Studied range
- TirzepatideFDA label: 2.5–15 mg, starting dose 2.5 mg.
- VK2735Research range: 2.5–17.5 mg, starting dose 2.5 mg. Studied in research — not a recommendation.
- How often
- TirzepatideWeekly
- VK2735Weekly
- Half-life
- Tirzepatide~5 days (FDA label)
- VK2735~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023)
- Route
- TirzepatideSubQ injection
- VK2735SubQ injection
- Typical run
- TirzepatideFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.
- VK2735Used continuously, once weekly, in its trials: 13 weeks in phase 2 and 78 weeks in phase 3. In Viking's maintenance study, people who switched after 21 weekly doses to a shot every other week or once a month kept most of their loss over the next 12 weeks; on placebo they kept about 61%.
- Evidence
- TirzepatideEstablished: clinical trials or FDA-approved use exists
- VK2735Moderate: animal studies + some human data
- Common side effects
- TirzepatideNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue
- VK2735Nausea, constipation, diarrhea, vomiting, acid reflux, fatigue, dry mouth
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Tirzepatide
- Day 1–28 · 2.5 mg Getting your gut acclimated
- Day 29–56 · 5 mg First therapeutic dose — weight drops
- Day 57–112 · 7.5 mg Dual agonism in full effect
- Day 113–168 · 12.5 mg Max titration reached
- Day 169–504 Weeks 24 to 72: where most people plateau
- Day 365+ A maintenance medication, not a course
VK2735
- Day 1–21 · 2.5 mg Low start, first weeks
- Day 22–91 The first 13 weeks
- Day 22–546 · 7.5 mg The lowest phase 3 dose
- Day 43–546 · 12.5 mg The middle phase 3 dose
- Day 43–546 · 17.5 mg The top phase 3 dose
- Day 150+ Holding the loss on fewer shots
Questions people ask
How long do tirzepatide and VK2735 last?
The half-life of tirzepatide is ~5 days (FDA label). The half-life of VK2735 is ~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023).
How often are tirzepatide and VK2735 taken?
Tirzepatide: weekly. Route: SubQ injection. VK2735: weekly. Route: SubQ injection.
How are tirzepatide and VK2735 dosed in research?
The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The research range for VK2735 is 2.5–17.5 mg, with a 2.5 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of tirzepatide and VK2735?
For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For VK2735: nausea, constipation, diarrhea, vomiting, acid reflux, fatigue, dry mouth.